Orthofix Medical (Orthofix Medical) ROCE % : -9.28% (As of Dec. 2023)

View and export this data going back to 1992. Start your Free Trial

What is Orthofix Medical ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Orthofix Medical's annualized ROCE % for the quarter that ended in Dec. 2023 was -9.28%.

Orthofix Medical ROCE % Historical Data

The historical data trend for Orthofix Medical's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Orthofix Medical ROCE % Chart

Orthofix Medical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

-6.80

0.51

-2.94

-4.40

-24.68

Orthofix Medical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-7.24	-40.91	-19.05	-14.18	-9.28

Orthofix Medical ROCE % Calculation

Orthofix Medical's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-140.048	/	( ( (458.629 - 83.624)	+	(925.315 - 165.223) )	/ 2 )
	=	-140.048	/	( (375.005	+	760.092)	/ 2 )
	=	-140.048	/	567.5485
	=	-24.68 %

Orthofix Medical's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-70.196	/	( ( (905.652 - 152.53)	+	(925.315 - 165.223) )	/ 2 )
	=	-70.196	/	( ( 753.122	+	760.092 )	/ 2 )
	=	-70.196	/	756.607
	=	-9.28 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

Orthofix Medical (NAS:OFIX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Orthofix Medical ROCE % Related Terms

Thank you for viewing the detailed overview of Orthofix Medical's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Orthofix Medical (Orthofix Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Orthofix Medical Inc (NAS:OFIX) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

OM2:Germany

Address

3451 Plano Parkway, Lewisville, TX, USA, 75056

Website

https://www.orthofix.com

Orthofix Medical Inc. is a medical device company delivering orthopedic and spine solutions to healthcare providers. The company has two main segments: global spine, including bone growth and healing therapies, spinal implants, and regenerative tissue products; and global orthopedics, providing products used in fracture repair, deformity correction, and bone reconstruction procedures. The majority of the company's sales come from the global spine segment in the United States. Orthofix distributes its products throughout North America, Europe, and several countries globally. The company provides solutions to hospitals, physicians, other healthcare providers, and patients.

Executives

James F. Hinrichs	director	3750 TORREY VIEW COURT, SAN DIEGO CA 92130
Puja Leekha	officer: CECO & Interim CLO	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Geoffrey C Gillespie	officer: VP, Controller, Interim CFO	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kevin J. Kenny	officer: President of Global Spine	C/O CARDIOVASCULAR SYSTEMS, INC., 1225 OLD HIGHWAY 8 NW, ST. PAUL MN 55112
Shweta Maniar	director	C/O SEASPINE HOLDINGS CORP, 5770 ARMADA DRIVE, CARLSBAD CA 92008
Stuart Essig	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
John J. Bostjancic	officer: CFO	C/O SEASPINE HOLDINGS CORPORATION, 2302 LA MIRADA DRIVE, VISTA CA 92081
Keith Valentine	director, officer: President & CEO	7475 LUSK BLVD., SAN DIEGO CA 92121
Henneman John B Iii	director	311 C ENTERPRISE DRIVE, PLAINSBORO NJ 08536
Patrick L Keran	officer: Chief Legal Officer	6725 MESA RIDGE RD., SUITE 100, SAN DIEGO CA 92121
Thomas A. West	director	C/O INTERSECT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Michael E Paolucci	director	7475 LUSK BLVD., SAN DIEGO CA 92121
Catherine M Burzik	director
Rice Doug	officer: CFO	3451 PLANO PARKWAY, LEWISVILLE TX 75056
Kimberley A. Elting	officer: Chief Legal Officer	3451 PLANO PARKWAY, LEWISVILLE TX 75056